Drug Shortage Report for ZYPREXA INTRAMUSCULAR

Last updated on 2022-12-22 History
Report ID 166551
Drug Identification Number 02247099
Brand name ZYPREXA INTRAMUSCULAR
Common or Proper name Olanzapine tartrate for injection
Company Name ELI LILLY CANADA INC
Market Status MARKETED
Active Ingredient(s) OLANZAPINE
Strength(s) 10MG
Dosage form(s) POWDER FOR SOLUTION
Route of administration INTRAMUSCULAR INTRAMUSCULAR
Packaging size 5 mL vial
ATC code N05AH
ATC description ANTIPSYCHOTICS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date 2022-08-26
Actual start date 2022-08-26
Estimated end date 2023-02-23
Actual end date
Shortage status Actual shortage
Updated date 2022-12-22
Company comments Shortage can be intermittent as Lilly may receive partial shipments, until full resolution expected on “Estimated end date”. The availability date represents estimated availability at the main Lilly warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date, or to contact our Lilly Customer Response Centre at 1-888-545-5972 (Monday-Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays) for more information.
Health Canada comments
Tier 3 Status No
Contact Address EXCHANGE TOWER, 130 KING STREET WEST
TORONTO, ONTARIO
CANADA M5X 1B1
Company contact information Lilly Canada’s Customer Response Centre 1-888-545-5972.

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v11 2022-12-22 French Compare
v10 2022-12-22 English Compare
v9 2022-11-15 French Compare
v8 2022-11-15 English Compare
v7 2022-11-07 French Compare
v6 2022-11-07 English Compare
v5 2022-08-27 English Compare
v4 2022-08-26 French Compare
v3 2022-08-26 English Compare
v2 2022-08-12 French Compare
v1 2022-08-12 English Compare

Showing 1 to 11 of 11